Columbia Partners L L C Investment Management lifted its holdings in shares of AxoGen, Inc. (NASDAQ:AXGN) by 11.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 286,146 shares of the medical equipment provider’s stock after buying an additional 30,176 shares during the quarter. Columbia Partners L L C Investment Management owned about 0.86% of AxoGen worth $4,792,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the stock. Parametric Portfolio Associates LLC lifted its stake in shares of AxoGen by 0.9% during the 1st quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock valued at $113,000 after buying an additional 93 shares in the last quarter. Nationwide Fund Advisors lifted its stake in shares of AxoGen by 5.5% during the 2nd quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock valued at $249,000 after buying an additional 774 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of AxoGen by 8.7% during the 1st quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 814 shares in the last quarter. American International Group Inc. lifted its stake in shares of AxoGen by 7.7% during the 1st quarter. American International Group Inc. now owns 14,941 shares of the medical equipment provider’s stock valued at $156,000 after buying an additional 1,068 shares in the last quarter. Finally, UBS Group AG lifted its stake in shares of AxoGen by 8.3% during the 1st quarter. UBS Group AG now owns 16,141 shares of the medical equipment provider’s stock valued at $169,000 after buying an additional 1,234 shares in the last quarter. Institutional investors own 66.77% of the company’s stock.

In related news, Director Robert James Rudelius sold 16,143 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $18.00, for a total transaction of $290,574.00. Following the completion of the sale, the director now directly owns 43,273 shares in the company, valued at $778,914. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.33% of the company’s stock.

A number of analysts recently commented on AXGN shares. Cantor Fitzgerald restated a “buy” rating and set a $18.00 price target on shares of AxoGen in a research note on Monday, August 21st. ValuEngine upgraded shares of AxoGen from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Roth Capital restated a “buy” rating and set a $21.00 price target (up from $18.00) on shares of AxoGen in a research note on Tuesday, September 12th. BidaskClub cut shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Finally, Leerink Swann started coverage on shares of AxoGen in a research note on Monday, July 31st. They set an “outperform” rating and a $22.00 price target on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. AxoGen currently has a consensus rating of “Buy” and an average target price of $17.20.

COPYRIGHT VIOLATION NOTICE: “Columbia Partners L L C Investment Management Acquires 30,176 Shares of AxoGen, Inc. (AXGN)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/18/columbia-partners-l-l-c-investment-management-acquires-30176-shares-of-axogen-inc-axgn.html.

AxoGen, Inc. (AXGN) traded up 0.946% during mid-day trading on Monday, reaching $18.675. 120,963 shares of the company’s stock traded hands. The stock has a 50 day moving average of $16.39 and a 200 day moving average of $14.01. AxoGen, Inc. has a 12-month low of $7.65 and a 12-month high of $18.75. The company’s market cap is $620.76 million.

AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $15.20 million during the quarter, compared to analyst estimates of $14.40 million. AxoGen had a negative net margin of 27.50% and a negative return on equity of 114.64%. The firm’s quarterly revenue was up 46.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.09) earnings per share. On average, equities research analysts predict that AxoGen, Inc. will post ($0.31) earnings per share for the current fiscal year.

AxoGen Profile

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Institutional Ownership by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Stock Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related stocks with our FREE daily email newsletter.